Against the backdrop of sustained growth in the global peptide drug industry, and steadily increasing global client demand for GLP-1-class peptides, peptide-drug conjugates (PDCs), peptide CDMO services, and related capabilities, JYMed Peptides (hereinafter referred to as “JYMed” or “the Company”) has specialized in peptide API development and manufacturing and contract development and manufacturing (CDMO) services for 17 years. The Company has established business partnerships with numerous clients across more than 40 countries and regions worldwide, and maintains local business development teams in key markets including Europe, the Americas, the Middle East, India, the CIS region, and Latin America, providing client support across major global pharmaceutical markets. Based on its medium- to long-term client order pipeline and the expected conversion of pipeline projects into orders, the Company has recently initiated a new round of planning for additional peptide API production lines to further strengthen its capabilities in large-scale peptide synthesis and purification, pilot-scale manufacturing, and commercial manufacturing, while meeting the growing demand for custom development and API supply of clients in China and international markets.

Existing Capacity Base and Positioning of the Current Plan

Following the completion of Workshop A16 at JYMed’s Hubei production base, the base will reach an annual peptide API production capacity of 10 metric tons, with overall reactor volume increasing to 85,000 liters. The current plan builds on the existing capacity of the Hubei production base and will further evaluate options for additional production lines to address clearly identified medium- to long-term growth in order volumes and changing product mix requirements. The planning will focus on systematic assessments covering GMP-compliant production line layouts for peptide APIs, green and smart manufacturing, environmental support systems, flexible multiproduct manufacturing, and adaptability to the process requirements of innovative drug modalities such as PDCs and long-chain peptides.

Related Business Developments

In 2026, the Company successfully passed a quality audit conducted by a top-tier multinational pharmaceutical company and was officially approved as a qualified supplier of peptide APIs. This milestone demonstrates that the Company’s quality systems, production management, and compliance capabilities met the supplier qualification standards of an internationally recognized pharmaceutical company, opening the door for subsequent large-scale commercial orders and serving as a key demand driver for this new production line planning initiative.

At the same time, the Company appointed Professor Fernando Albericio as Chief Scientist and Dr. Beatriz G. de la Torre as Senior Scientist this year. Both experts bring deep academic expertise and extensive experience in industrial-scale peptide development and peptide medicinal chemistry, synthetic process development, and optimization of complex peptide synthetic routes. Their appointments have further strengthened the Company’s technological capabilities in cutting-edge areas such as novel molecular design for peptide-drug conjugates and innovative synthetic process development, supporting the planning of future production capabilities for high-value, complex peptide products.

Pre-Planning Work Arrangements

To facilitate scientifically sound capacity expansion decisions, the Company plans to engage professional firms with expertise in pharmaceutical engineering and biopharmaceutical industry planning to conduct systematic feasibility and planning studies for the new production lines. The studies will cover core areas, including market demand analysis, process route and equipment selection, GMP compliance system evaluation, environmental and utility engineering support, and capital cost estimation and economic assessment, ensuring that capacity expansion decisions are grounded in robust data and professional analysis.

At present, this work remains at the preliminary planning and research stage. Specific investment levels and construction timelines have not yet been finalized, and the plan may still be adjusted, deferred, or discontinued.

Looking ahead, JYMed Peptides will continue to strengthen its end-to-end peptide CRDMO capabilities, leveraging its client network and on-the-ground service teams covering major global markets, along with its quality systems assessed through audits by international pharmaceutical companies, to steadily expand its presence in domestic and overseas markets and solidify its position as a reliable partner in the global peptide supply chain.

JYMed Peptide – A leading global peptide solutions provider.